Business Context and Reporting Period
This Form 8-K filing by Supernus Pharmaceuticals, Inc. covers events occurring on August 6 and August 7, 2013. The company is a Delaware corporation focused on pharmaceutical development, specifically highlighting its antiepileptic drug Oxtellar XRTM.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of an upcoming earnings announcement rather than a financial statement itself.
Material Changes and Events
- Earnings Announcement: On August 6, 2013, the company announced it will report financial results for the three and six months ended June 30, 2013, after market close on August 13, 2013. A conference call and webcast are scheduled for that date.
- Patent Litigation: On August 7, 2013, Supernus initiated litigation against generic drug makers Actavis Inc., Watson Laboratories, Inc., Actavis Pharma, Inc., and Anda, Inc. (collectively "Watson").
- Legal Basis: The lawsuit, filed in the U.S. District Court for the District of New Jersey, alleges infringement of two patents covering Oxtellar XRTM. The defendants submitted an Abbreviated New Drug Application (ANDA) to the FDA to market a generic version prior to patent expiration.
- Patent Expiration: The patents in question do not expire until April 13, 2027.
Guidance, Outlook, and Risks
The filing indicates an upcoming update on business matters during the August 13 conference call. The primary risk disclosed is the potential loss of market exclusivity for Oxtellar XRTM due to the generic entry attempt by Watson, which the company is actively contesting through litigation.
Investor Verification Checklist
- Verify the specific financial results for the quarter and half-year ended June 30, 2013, once released on August 13, 2013.
- Monitor the status of the litigation against Watson regarding the Oxtellar XRTM patents.
- Confirm the timeline of the FDA's response to the Abbreviated New Drug Application (ANDA) filed by the defendants.
- Review the full text of the press releases attached as Exhibits 99.1 and 99.2 for additional details not summarized here.